- Home
- STTK vs NUKK Comparison
STTK vs NUKK Comparison
Compare STTK & NUKK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- NUKK
- Stock Information
- Founded
- STTK 2016
- NUKK 2013
- Country
- STTK United States
- NUKK United States
- Employees
- STTK N/A
- NUKK N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- NUKK Blank Checks
- Sector
- STTK Health Care
- NUKK Finance
- Exchange
- STTK Nasdaq
- NUKK Nasdaq
- Market Cap
- STTK 112.6M
- NUKK 100.0M
- IPO Year
- STTK 2020
- NUKK N/A
- Fundamental
- Price
- STTK $1.96
- NUKK $5.15
- Analyst Decision
- STTK Hold
- NUKK
- Analyst Count
- STTK 5
- NUKK 0
- Target Price
- STTK $3.00
- NUKK N/A
- AVG Volume (30 Days)
- STTK 162.8K
- NUKK 1.7M
- Earning Date
- STTK 11-06-2025
- NUKK 11-14-2025
- Dividend Yield
- STTK N/A
- NUKK N/A
- EPS Growth
- STTK N/A
- NUKK N/A
- EPS
- STTK N/A
- NUKK N/A
- Revenue
- STTK $1,000,000.00
- NUKK N/A
- Revenue This Year
- STTK N/A
- NUKK N/A
- Revenue Next Year
- STTK N/A
- NUKK N/A
- P/E Ratio
- STTK N/A
- NUKK N/A
- Revenue Growth
- STTK N/A
- NUKK N/A
- 52 Week Low
- STTK $0.69
- NUKK $1.30
- 52 Week High
- STTK $2.71
- NUKK $78.32
- Technical
- Relative Strength Index (RSI)
- STTK 49.33
- NUKK 36.56
- Support Level
- STTK $1.86
- NUKK $6.05
- Resistance Level
- STTK $2.06
- NUKK $6.32
- Average True Range (ATR)
- STTK 0.14
- NUKK 0.89
- MACD
- STTK -0.00
- NUKK -0.31
- Stochastic Oscillator
- STTK 43.64
- NUKK 15.91
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About NUKK Nukkleus Inc.
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).